4182:TSEMitsubishi Gas Chemical Company, Inc. Analysis
Data as of 2026-05-26 - not real-time
¥5,435.00
Latest Price
7/10Risk
Risk Level: Medium
Executive Summary
Mitsubishi Gas Chemical is trading well above its key moving averages (20‑day SMA ~4,707, 50‑day SMA ~4,310, 200‑day SMA ~3,318) and sits near its 52‑week high of 5,526, indicating a strong bullish backdrop. However, the RSI of 73 signals an overbought condition and the stock may face short‑term pressure around the identified resistance level. Technical momentum remains supportive, with a bullish MACD crossover and increasing volume reinforcing the upward trend. Fundamentally, the company is priced far above its DCF fair value of ~2,694, yielding an upside/downside metric of about -13%, suggesting it is currently overvalued. Despite a negative trailing EPS, forward EPS is projected positive at 276.36, and the firm generates solid operating cash flow, supporting its 2.1% dividend yield with a payout ratio near 41%. The balance sheet is strained, featuring a high debt load (debt‑to‑equity ~33) and a recent net loss, which raises concerns about long‑term sustainability.
Given the blend of bullish technical signals, a modest dividend, and an anticipated earnings turnaround, the stock may appeal to value‑oriented investors seeking yield, but the valuation premium and debt profile warrant caution. Short‑term traders should monitor the overbought RSI and resistance breakout, while medium‑ to long‑term holders should focus on the company’s ability to convert forward earnings expectations into actual profitability and manage its leverage.
Given the blend of bullish technical signals, a modest dividend, and an anticipated earnings turnaround, the stock may appeal to value‑oriented investors seeking yield, but the valuation premium and debt profile warrant caution. Short‑term traders should monitor the overbought RSI and resistance breakout, while medium‑ to long‑term holders should focus on the company’s ability to convert forward earnings expectations into actual profitability and manage its leverage.
Market Outlook
Short Term
< 1 yearNeutral
Model confidence: 6/10
Key Factors
- RSI overbought at 73 suggesting potential pullback
- Price near 52‑week high and resistance level
- Bullish MACD and rising volume supporting trend
Medium Term
1–3 yearsPositive
Model confidence: 7/10
Key Factors
- Forward EPS positive indicating earnings recovery
- Sustainable dividend yield of 2.1% with moderate payout
- Technical trend remains bullish with price above all SMAs
Long Term
> 3 yearsNeutral
Model confidence: 5/10
Key Factors
- Significant valuation gap versus DCF fair value
- High debt‑to‑equity ratio posing balance‑sheet risk
- Potential for dividend continuity if cash flow improves
Key Metrics & Analysis
Financial Health
Revenue Growth-0.90%
Profit Margin-5.46%
P/E Ratio19.7
ROE-4.96%
ROA2.54%
Debt/Equity33.00
P/B Ratio1.6
Op. Cash Flow¥74.7B
Free Cash Flow¥-23187625984
Technical Analysis
TrendBullish
RSI73.0
Support¥4,212.00
Resistance¥5,526.00
MA 20¥4,707.15
MA 50¥4,309.56
MA 200¥3,318.35
MACDBullish
VolumeIncreasing
Fear & Greed Index91.36
Valuation
Fair Value¥2,694.42
Target Price¥4,722.73
Upside/Downside-13.11%
GradeOvervalued
TypeValue
Dividend Yield2.10%
Risk Assessment
Beta0.07
Volatility45.58%
Sector RiskMedium
Reg. RiskMedium
Geo RiskLow
Currency RiskLow
Liquidity RiskLow
Similar Tickers
This analysis may contain inaccuracies and is provided for informational and research purposes only. It is not personal investment advice, a recommendation, or an instruction to buy, sell, or hold any asset.